AI Article Synopsis
- Rheumatoid arthritis (RA) is a long-term autoimmune condition that affects multiple joints and can lead to disability, largely driven by activated macrophages.
- Researchers developed a new treatment called dextran sulfate-methotrexate (DS-MTX), which targets scavenger receptors on activated macrophages to improve therapy effectiveness for RA.
- DS-MTX showed better results in reducing inflammation and accumulating in affected joints compared to the standard treatment, highlighting its potential as a new therapy for RA patients.
Article Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder implicated in multiple joint affection and even disability. The activated macrophages perform a predominant role in onset and persistence of RA. Scavenger receptor (SR), one of several receptors overexpressed on the activated macrophages, is a specific biomarker for targeted therapy of numerous chronic inflammation diseases like RA. In this work, dextran sulfate--methotrexate conjugate (DS--MTX) is synthesized and characterized, which exhibits excellent targetability to SR on the activated RAW 264.7 cells. Additionally, the enhanced accumulation and potent inflammatory inhibition are observed in the affected joint after intravenous injection of DS--MTX, compared to the treatment with dextran--methotrexate (Dex--MTX), as is confirmed by the detection of histopathology and pro-inflammatory cytokines. Our work highlights DS--MTX as a potential therapeutic option for RA aiming the SR-expressed activated macrophages.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5196888 | PMC |
| http://dx.doi.org/10.7150/thno.16844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!